Contact Congress about S. 3677: Dietary Supplement Listing Act of 2026

Supplement companies would have to report each product to the FDA. The FDA would create a public database with labels, ingredients, serving details, warnings, and certain claims. The bill keeps supplements outside FDA pre-sale approval.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Dietary Supplement Listing Act of 2026 is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S259-260).

Latest action on S. 3677: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S259-260)

Who this affects: This bill mainly affects supplement makers, packers, distributors, and foreign companies that sell supplements in the United States. They would need to file product listings, update them on deadlines, and track facility information for FDA requests. Consumers, health care providers, and researchers could use the public database to check official product information. FDA would need to build and run the new listing system.

Why this matters: Today, there is no single public FDA list of all dietary supplements sold in the United States. This bill would create one and make companies keep product information current. That could help people compare labels and help FDA find products faster during safety reviews, recalls, or inspections. The bill may also add costs and paperwork for companies, especially smaller businesses with many products.

Key provisions in S. 3677

• The bill creates a new supplement listing rule in federal food and drug law. Every dietary supplement sold in the United States would have to be listed with the FDA.
• Companies would have to send FDA detailed product information. That includes the product name, label images, all ingredients, proprietary blends, serving details, directions, warnings, allergens, product form, and certain health-related claims.
• One filing could cover several very similar supplements. That only applies when they have the same or nearly the same formula and differ only by color, inactive ingredients, flavoring, or package size.
• Products already on the market would have to be listed within 18 months after the law takes effect. New products would have to be listed when they first enter interstate commerce, meaning when they are sold or moved across state lines.
• Companies would have to tell FDA within 1 year after they stop selling a listed supplement. They would also have to update a listing within 30 days after a changed label first appears in commerce.

How Modern Action helps you take action on S. 3677

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 3677

What is S. 3677?

Supplement companies would have to report each product to the FDA. The FDA would create a public database with labels, ingredients, serving details, warnings, and certain claims. The bill keeps supplements outside FDA pre-sale approval.

How do I support or oppose S. 3677?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 3677?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 3677 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.